header logo image


Page 988«..1020..987988989990..1,0001,010..»

Breakthrough Nanorod Tech Could Deliver Gene Therapy Directly to Cancer Cells – Technology Networks

July 11th, 2017 9:49 am

A new method efficiently transfers genes into cells, then activates them with light. This could lead to gene therapies for cancers

Mineko Kengaku, Tatsuya Murakami, and their colleagues from Kyoto Universitys Institute for Integrated Cell-Material Sciences (iCeMS) have developed a new method that modifies the surface of nanorods, making them more efficient in transporting cancer-killing genes into cells.

The method involves coating gold nanorods, which produce heat when exposed to a near-infrared laser, with the lipids oleate and DOTAP. The lipids enhance the nanorods' ability to interact with and penetrate cells.

The team also developed a gene carrier, known as a plasmid vector, which includes a heat shock protein that is activated in response to heat.

First, the vector was bound to the enhanced green fluorescent protein (EGFP) gene, and then transferred into mammalian cells by the lipid-coated gold nanorods. Exposing cells to near-infrared laser for ten seconds heated up the gold nanorods, turning on the EGFP gene. Surrounding, non-targeted cells showed little to no EGFP expression.

A protein called TRAIL was then added to the plasmid vector. TRAIL induces cell death in cancer cell lines. Infrared illumination of cells transfected by TRAIL-carrying nanorods led to a high cell death rate in surrounding cancer cells.

The lipid-coated gold nanorods could potentially help with molecular cancer therapies.

This new system provides a unique opportunity for site-directed, light-inducible transgene expression in mammalian cells by a near-infrared laser, with minimal phototoxicity, conclude the researchers in their study published in the journal Scientific Reports.

This article has been republished frommaterialsprovided by Kyoto University. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference

Nakatsuji, H., Kawabata, G. K., Kurisu, J., Imahori, H., Murakami, T., & Kengaku, M. (2017). Surface chemistry for cytosolic gene delivery and photothermal transgene expression by gold nanorods. Scientific reports, 7(1), 4694.

See more here:
Breakthrough Nanorod Tech Could Deliver Gene Therapy Directly to Cancer Cells - Technology Networks

Read More...

BioMarin’s Investigational Gene Therapy for Hemophilia A at 6e13 … – PR Newswire (press release)

July 11th, 2017 9:49 am

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. The updated results will be presented by John Pasi, Ph.D. F.R.C.P, at Barts and the London School of Medicine and Dentistry and Haemophilia Clinical Director at Barts Health NHS Trust and primary investigator for the BMN 270 Phase 1/2 clinical trial, during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress being held July 8-13, 2017 in Berlin, Germany. Professor Pasi will present the data in a late breaking abstract on July 11, 2017, which will be the only clinical data in gene therapy for hemophilia A to be presented at the meeting.

In the open-label Phase 1/2 study, a total of 15 patients with severe hemophilia A1(defined by the World Federation of Hemophilia (WFH) as having Factor VIII activity levels less than 1%, expressed as a percentage of normal factor activity in blood) received a single dose of BMN 270, seven of whom were treated at a dose of 6e13 vg/kg and an additional six of whom were subsequently treated at a lower dose of 4e13 vg/kg. The other two patients in the study were treated at lower doses as part of dose escalation in the study and did not achieve therapeutic efficacy. According to the WFH rankings of severity of hemophilia A, the normal range of Factor VIII activity levels for people without disease is between 50% and 150%, expressed as a percentage of normal factor activity in blood, and the mild hemophilia A range of Factor VIII activity levels is between 5% and 40%. (See Table 6 for further information on severity levels)

As of the May 31, 2017 data cutoff, all patients at the 6e13 vg/kg dose had reached 52 weeks of post-treatment follow-up. Median and mean Factor VIII levels from week 20 through 52 for the 6e13 vg/kg dose cohort have been consistently within the normal levels post treatment as a percentage calculated based on the numbers of International Units per deciliter (IU/dL) of plasma. (See Table 1). At one year after dosing, the median and mean Factor VIII levels of the 6e13 vg/kg cohort continue to be above 50%. (See Table 6)

Table 1: Factor VIII Levels (%) of 6e13 vg/kg Dose Patients* by Visit (N=7)

Week**

20

24

28

32

36

40

44

48

52

6e13 vg/kg Dose

N***

7

7

7

6

7

7

7

7

7

Median

Factor VIII Level**** (%)

97

101

122

99

99

111

105

105

89

Mean

Factor VIII Level**** (%)

118

129

123

122

116

124

122

106

104

Range

(low, high)

(12, 254)

(12, 227)

(15, 257)

(26, 316)

(31, 273)

(17, 264)

(20,242)

(23,196)

(20, 218)

*All patients had severe hemophilia A, defined as less than 1% of Factor VIII activity levels, expressed as a percentage of normal factor activity in blood. **Weeks were windowed by +/- 2 weeks ***For week 32, one patient had no Factor VIII reading ****Bolded numbers are in the normal range of Factor VIII as defined by the World Federation of Hemophilia, http://www.wfh.org/en/page.aspx?pid=643 (link current as of June 30, 2017). Factor VIII levels are determined by one-stage assay.

The median and mean Factor VIII levels from week 8 to 24 for all patients observed at the 4e13 vg/kg dose are in the mild level. Three of these subjects who have been observed for 24 weeks are at the upper end of mild. (See Table 2 for Factor VIII levels and Table 6 for severity levels)

Table 2: Factor VIII Levels (%) of 4e13 vg/kg Dose Patients* by Visit (N=6)

Week**

4

8

12

16

20

24

4e13 vg/kg Dose

n

6

6

6

3

3

3

Median

Factor VIII Level*** (%)

4

15

21

35

37

33

Mean

Factor VIII Level*** (%)

5

13

19

33

38

33

Range

(low, high)

(2,10)

(3,21)

(6,32)

More here:
BioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 ... - PR Newswire (press release)

Read More...

uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene … – GlobeNewswire (press release)

July 11th, 2017 9:49 am

July 11, 2017 06:30 ET | Source: uniQure N.V.

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 11, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today presented new clinical data demonstrating that the presence of pre-existing anti-AAV5 neutralizing antibodies (NABs) does not predict the potential efficacy of AAV5-mediated gene transfer in patients with hemophilia B. Clinically meaningful factor IX (FIX) activity levels from the ongoing Phase I-II trial of AMT-060 were observed at NAB titers up to 1:341, determined as corresponding up to the 90th percentile of a healthy control population. NABs were quantified in the blood sera of these patients using a highly sensitive assay. These clinical data were presented today in a poster presentation at the 26th Biennial Congress of theInternational Society on Thrombosis and Hemostasis(ISTH), taking place this week in Berlin, Germany.

The presence of pre-existing NABs to adeno-associated virus (AAV) vectors has long posed a critical challenge for the clinical application of gene therapies, as patients who currently screen positive for NABs are generally excluded from treatment. Researchers from uniQure recently presented data in non-human primates suggesting that AAV5 could successfully mediate gene transfer in the presence of NABs at levels as high as 1:1031.

In a poster presentation at the ISTH meeting, a re-analysis was described of pre-gene transfer screening samples from the 10 patients who have been treated in the ongoing Phase I/II trial of AMT-060 for hemophilia B. The patients had tested negative for preexisting anti-AAV5 NAbs using a green fluorescent proteinbased (GFP) assay before receiving treatment. These samples were later re-assessed using a highly sensitive luciferase-based (LUC) NAB assay. Anti-AAV5 NABs were detected retrospectively in three patients who had been treated with the low dose (5x1012 gc/kg) of AMT-060. However, all three patients presented increases in FIX expression and, especially, the patient with the highest NAB level (titer 1:341) had the highest FIX-activity (steady-state FIX 6.8% of normal; latest FIX measurement 10.7% of normal) among all five patients treated in the low-dose cohort. None of the three patients who tested positive for NAB titers, experienced over time elevations in liver enzymes post gene transfer, FIX activity loss, or clinically relevant T-cell responses to the capsid.

These clinical data show that hemophilia B patients presenting with neutralizing antibodies may be considered eligible for AAV5-mediated gene transfer, stated Matthew Kapusta, chief executive officer at uniQure. This development potentially expands the applicability of AAV5 gene therapies to nearly all hemophilia B patients. We believe these factors contribute to making AAV5 a potential best-in-class vector for delivering gene therapies more effectively and safely to a greater portion of patients in need of treatment.

About uniQure uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntingtons disease and cardiovascular diseases. http://www.uniQure.com

uniQure Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates, including the future development of AMT-060, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with corporate reorganizations and strategic shifts, collaboration arrangements, our and our collaborators clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQures 2016 Annual Report on Form 10-K filed on March 15, 2017. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Related Articles

Lexington, Massachusetts, UNITED STATES

Link:
uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene ... - GlobeNewswire (press release)

Read More...

Colon Cancer-Driven Stem Cells Linked to High-Fat Diet – Genetic Engineering & Biotechnology News

July 11th, 2017 9:49 am

Scientists in the U.S. have identified a molecular pathway that appears to play a key role in the link between a high-fat diet (HFD) and the development of colorectal cancer. The research, led by the Cleveland Clinics Sheerlarani Karunanithi, and Matthew Kalady, suggests that it may one day be possible to develop drugs that reduce tumor growth associated with obesity and a diet that is high in fat.

Their research is published today, in Stem Cell Reports, in a paper titled, RBP4-STRA6 Pathway Drives Cancer Stem Cell Maintenance and MediatesHigh-Fat Diet-Induced Colon Carcinogenesis.

The Cleveland Clinic teams review of published research indicated that high expression levels of two vitamin A signalling proteinsserum retinol binding protein (RPB4), stimulated by retinoic acid 6 (STRA6)in colorectal cancer tumors is associated with poor prognosis, increased tumor metastasis and recurrence, and resistance to cancer therapy. The RBP4-STRA6 pathway triggers the JAK2-STAT3 signaling cascade.

The researchers engineered STRA6- or RBP4-knockdown cancer cells to demonstrate that the RBP4-STRA6 pathway is important for promoting cancer cell proliferation and survival and for maintaining the expression of core stem cell transcription factors. They also found that the RBP4-STRA6 pathway plays a key role in maintaining colon cancer stem cells (CSCs), both in cell lines and in patient-derived xenografts.

The teams previous work had shown that knocking down STRA6 in a xenograft cancer model decreased tumor growth. In a new round of studies, they injected RBP4-knockdown cancer cells into experimental mice, and found that RBP4 deficiency resulted in the development of fewer tumors, and slower tumor growth and progression.

With evidence building for the role of RBPA4-STRA6 pathway in colorectal cancer development and progression, the team turned to look at diet-related cancer. A prior study had already suggested that HFDinduced obesity leads to increased intestinal stem cells and may impact colorectal cancer risk. This finding, combined with independent research establishing a role for the RBPA4-STRA6 pathway in diet-induced metabolic syndrome, prompted the Cleveland Clinic team to look at the relationship between HFD, cancer development, and the RBPA4-STRA6 pathway.

They injected either STRA6-deficient colorectal cancer cells or unmodified cancer cells into obesity-resistant mice fed either a normal diet or an HFD. HFD mice injected with unmodified cancer cells exhibited significantly increased tumor growth compared with mice fed a normal diet. In contrast, there was no relative increase in tumor growth among HFD animals receiving the STRA6-deficient tumor cells.

Our data clearly indicate that RBP4-STRA6 pathway is necessary for the optimal expression of stem cell markers such as NANOG, SOX2, and LGR5, and thereby for maintaining the colon CSC pool, the authors conclude in their published paper. "We have known the influence of diet on colorectal cancer, commented Matthew Kalady, M.D., colorectal surgeon, and co-director of the Cleveland Clinic Comprehensive Colorectal Cancer Program. However, these new findings are the first to show the connection between high-fat intake and colon cancer via a specific molecular pathway. We can now build upon this knowledge to develop new treatments aimed at blocking this pathway and reducing the negative impact of a high-fat diet on colon cancer risk."

The interesting finding here is that the high fat diet-induced effects appear to also involve the stem cell program, which is interesting for tumor growth and has implications on therapies, as tumor stem cells are also therapeutically resistant, the authors told GEN. In terms of treatments, what we might envision is targeting a new component of the signaling axis we identified to reduce cancer growth. The pathways we have identified are known to control many aspects of cell behavior, but the input to these signaling programs is new and may represent a possible target. In terms of next steps, one would be to see whether this can be applied to other obesity-driven tumors. Can lessons from colon cancer be leveraged to other tumor types? We also are interested in inhibiting this new signaling axis as well as trying to understand more about this signaling program, as we may be able to identify signaling nodes that can be efficiently targeted.

View original post here:
Colon Cancer-Driven Stem Cells Linked to High-Fat Diet - Genetic Engineering & Biotechnology News

Read More...

Injecting stomach fat into the scalp could CURE baldness in just six … – The Sun

July 11th, 2017 9:49 am

The Sun
Injecting stomach fat into the scalp could CURE baldness in just six ...
The Sun
INJECTING stomach fat into the scalp could be a radical new way of combating baldness, experts have revealed. The pioneering new method involves sucking ...

and more »

See original here:
Injecting stomach fat into the scalp could CURE baldness in just six ... - The Sun

Read More...

Kerastem UK Hair Growth Data Published – Benzinga

July 11th, 2017 9:49 am

Subjects receiving Kerastem therapy had a mean increase of 31 new hairs per sq. cm. of scalp at 6 months compared to Baseline

San Diego, California (PRWEB) July 11, 2017

Kerastem, the leader in cell-based approaches to hair growth, announced today that clinical data utilizing the Kerastem therapy for the treatment of female and male patterned baldness (genetic alopecia) was published in the peer reviewed Journal of Stem Cells and Cloning (Stem Cells and Cloning: Advances and Applications 2017, 10:1-10--https://doi.org/10.2147/SCCAA.S131431). The authors reported that all six (100%) subjects receiving Kerastem Therapy had an increase from baseline hair counts at 6 months, with initial results as early as 6 weeks. The investigators performed a single scalp injection of Kerastem Cell Therapy in 9 healthy hair loss patients, and a total of 6 patients were followed for a period of 6 months.

The authors reported a mean increase of 31 hairs per cm2 of scalp at 24 weeks compared to baseline, corresponding to a 23% increase (p = 0.017). Kerastem Therapy subjects saw up to a 53% increase in the number of hairs at 6 months. According to lead investigator Dr. David Perez-Meza, "We are very pleased with the clinical outcomes of our hair regeneration study, as they represent this procedure is safe and that results that are on par or better than those of traditional medical approaches to hair loss."

US PHASE II CLINICAL TRIAL ENROLLED (STYLE) The Kerastem therapy is based on the emerging science that adipose (fat) plays an important role in the normal hair growth cycle. The clinical approach utilizes purified adipose combined with stem and regenerative cells to deliver cell enriched tissue to the affected scalp. According to Dr. Eric Daniels, Chief Medical Officer of Kerastem, "Fat and fat derived cells are now appreciated as a dynamic, and vital participant in the normal cycle of hair growth. This data set from the United Kingdom further supports this position and we look forward to releasing top-line 24-week data from our fully enrolled STYLE trial later this year." Outside of the United States, the company is actively involved in market development, with Kerastem therapy currently being offered at a number of clinics in Europe & Japan. To learn more about Kerastem or the STYLE Clinical Trial, please visit http://www.kerastem.com.

ANDROGENETIC ALOPECIA MARKET SIZE Hair loss affects more than 21 million women and 40 million men in the United States alone. The global hair loss market is valued at more than $7 Billion and currently has limited options for women and men with early hair loss.

About Kerastem Kerastem is a leader in the development and commercialization of cell-based approaches to hair growth. The private company is a wholly owned subsidiary of Bimini Technologies. The Bimini portfolio also includes Puregraft, the world's leading fat transfer solution.

Cautionary Statement Regarding Forward-Looking Statements This press release may include "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as "will," "near future," "positioned," "provide," or other words or phrases of similar import that are intended to identify forward-looking statements. Similarly, statements herein that describe Kerastem LLC's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements, including: the clinical and commercial potential and success of the company's product line; general economic and business conditions; and other risks and important factors that could cause actual results to differ materially from the forward-looking statements. The forward-looking statements included in this press release are made only as of the date of this announcement, and Kerastem LLC undertakes no obligation to update the forward-looking statements to reflect subsequent events or circumstances after the date on which they were made.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/07/prweb14496474.htm

Go here to read the rest:
Kerastem UK Hair Growth Data Published - Benzinga

Read More...

Just smelling food can make you fat, UC Berkeley study says – SFGate

July 11th, 2017 9:49 am

Photo: Courtesy Of UC Berkeley / UC Berkeley

These mice ate the same high-fat diet in a UC Berkeley study, but the sense of smell was removed for the one on the right, helping it stay slim.

These mice ate the same high-fat diet in a UC Berkeley study, but the sense of smell was removed for the one on the right, helping it stay slim.

Real or not? Drink the ultimate San Francisco martini, made with a locally made vodka diluted with fog-derived water.

Real or not? Drink the ultimate San Francisco martini, made with a locally made vodka diluted with fog-derived water.

Real or not? If you're tired of traditional burritos, try a new fusion kind that turns a sushi roll into, well, a large burrito-sized sushi roll. Sheets of seaweed serve as the outer layer, with pieces of tuna sushi inside.

Real or not? If you're tired of traditional burritos, try a new fusion kind that turns a sushi roll into, well, a large burrito-sized sushi roll. Sheets of seaweed serve as the outer layer, with pieces of tuna

Real or not? In a nod to the city's gold mining history, try a decadent, $100 gold pizza the pie comes with white truffles, 24-month aged prosciutto, mushrooms and more. Oh! And there's gold flakes on top.

Real or not? In a nod to the city's gold mining history, try a decadent, $100 gold pizza the pie comes with white truffles, 24-month aged prosciutto, mushrooms and more. Oh! And there's gold flakes on top.

Fake. Although delicious-sounding, no such thing exists. Yet.

Fake. Although delicious-sounding, no such thing exists. Yet.

Real or not? Boring IPAs, step aside: Liven things up with a taco-inspired beer. With this IPA, drinkers will notice a tropical aroma, followed by notes of traditional Mexican seasonings, such as cumin, coriander and cilantro.

Real or not? Boring IPAs, step aside: Liven things up with a taco-inspired beer. With this IPA, drinkers will notice a tropical aroma, followed by notes of traditional Mexican seasonings, such as cumin,

Real: Cellarmaker Brewing Co. first brewed this beer in 2013, but brought back "Taco Hands" (as it's called) in time for Cinco de Mayo last year.

Real: Cellarmaker Brewing Co. first brewed this beer in 2013, but brought back "Taco Hands" (as it's called) in time for Cinco de Mayo last year.

Real or not? Craftsman & Wolves, makers of the "The Rebel Within" a brunchtastic muffin complete with egg inside is now going to serve its muffin sans egg.

Real or not? Craftsman & Wolves, makers of the "The Rebel Within" a brunchtastic muffin complete with egg inside is now going to serve its muffin sans egg.

Real or not? Sweet ice cream is for the unadventurous. Step outside the box with a prosciutto-flavored ice cream that is a cold and savory treat.

Real or not? Sweet ice cream is for the unadventurous. Step outside the box with a prosciutto-flavored ice cream that is a cold and savory treat.

Real or not? This is most likely the ultimate pork dish. If you're a fan, try a wood-oven roasted pig head that is cooked until its skin is crispy, complete with gold leaf melted on the tip of the snout.

Real or not? This is most likely the ultimate pork dish. If you're a fan, try a wood-oven roasted pig head that is cooked until its skin is crispy, complete with gold leaf melted on the tip of the snout.

Real or not? If you're a fan of both coffee and wine, not have both at once? Wine-infused coffee beans are the next frontier for those looking for a drink that infuses both worlds in a single cup.

Real or not? If you're a fan of both coffee and wine, not have both at once? Wine-infused coffee beans are the next frontier for those looking for a drink that infuses both worlds in a single cup.

Real or not? This is certainly not your normal slice of Kraft American cheese: Along with its normal goat cheese bits, is a specialty cheese that incorporates vegetable ash into the mix.

Real or not? This is certainly not your normal slice of Kraft American cheese: Along with its normal goat cheese bits, is a specialty cheese that incorporates vegetable ash into the mix.

Real or not? In a bid to rescue any dented or ugly leftover vegetables from the Ferry Plaza Farmer's Market, this business gathers them and creates a protein-laden power bar for customers.

Real or not? In a bid to rescue any dented or ugly leftover vegetables from the Ferry Plaza Farmer's Market, this business gathers them and creates a protein-laden power bar for customers.

Fake. Although the fictional power bar does fulfill a number of foodie credos (Locally sourced? Check. Nutritious? Check.), this one is false.

Fake. Although the fictional power bar does fulfill a number of foodie credos (Locally sourced? Check. Nutritious? Check.), this one is false.

Real or not? If you're a beer fan in the know, you know to look out for Girl Scout Cookie beers. This line of beers is based on five different cookies from the Girl Scout line, including Samoa, Do-Si-Dos, Thin Mint, Trefoil and Tagalongs.

Real or not? If you're a beer fan in the know, you know to look out for Girl Scout Cookie beers. This line of beers is based on five different cookies from the Girl Scout line, including Samoa, Do-Si-Dos, Thin

Real or not? Vegetarians can finally move away from the portobello mushroom "burger" and finally have a burger that is veggie, but has all the meaty burger qualities that carnivores love. This new veggie burger "bleeds," sears and develops a burger "crust" to the patty all while helping to alleviate the environmental impact of meat production.

Real or not? Vegetarians can finally move away from the portobello mushroom "burger" and finally have a burger that is veggie, but has all the meaty burger qualities that carnivores love. This new veggie burger

Just smelling food can make you fat, UC Berkeley study says

On the bustling streets of San Francisco, people can sense whats grilling, baking and frying in restaurants from North Beach to Noe Valley without even looking at the menus, as myriad cuisines serve up a smorgasbord of aromas for the nostrils.

But what most foodies and waist-watchers strolling by dont realize is that just smelling burgers, pizza, sushi, falafel or any of the other sweet and savory offerings could be causing them to gain weight.

A study by UC Berkeley researchers found that a sense of smell can influence the brains decision to burn fat or store it in the body or a least the bodies of mice.

Researchers Andrew Dillin and Celine Riera studied three groups of mice normal mice, super-smellers and ones without a sense of smell and saw a direct correlation between their ability to smell and how much weight they gained from a high-fat, Burger King diet, Dillin said.

Each mouse ate the same amount of food, but those with a super sense of smell gained the most weight.

The normal mice ballooned, too up to 100 percent from the weight they were when the research started.

But the mice who couldnt smell anything gained only 10 percent of their weight. Obese mice who had their sense of smell wiped out slimmed down to the size of normal counterparts without a change in diet.

Riera said the study, which was published this month in the journal Cell Metabolism, reveals that outside influences such as smell can affect the brains functions related to appetite and metabolism.

Other studies have shown that olfactory systems, the organs and lobes related to smell, can influence things like sexual behavior or fertility, but this study isnt related to internal functions or hormones, said Riera, a former UC Berkeley postdoctoral fellow now at Cedars-Sinai Medical Center in Los Angeles.

In the context of food and appetite, this is really novel, she said.

Using the studys methods in humans could be possible.

After eating, a persons sense of smell decreases. So, if a person was eating with a lessened sense of smell, the brain could be tricked into thinking its already been fed and choose to burn the calories instead of store them, Riera said.

People struggling with obesity could have their sense of smell wiped out or temporarily reduced to help them control cravings and burn calories and fat faster.

But there are risks.

People that dont have a sense of smell can get depressed, because the sense of smell is very important for behavior, Riera said. They lose all pleasure of eating.

People who lose their sense of smell from aging, injury or diseases like Parkinsons can also struggle with keeping weight on.

The mice in the study who lost their sense of smell also saw a significant increase in the hormone noradrenaline a stress response from the nervous system that can lead to a heart attack if levels are too high.

Eliminating a humans sense of smell would be a radical step, said Dillin, an expert in stem cell research. But it could also be an option for obese people who are considering such weight-reduction alternatives as stomach stapling or gastric-band surgery, even with the potential for high levels of noradrenaline.

In both humans and mice, decreasing or wiping out the sense of smell is only temporary. In the study, researchers injected a toxin that destroyed olfactory neurons in the nose, but they avoided the stem cells which allowed the neurons to grow back in three to eight weeks.

To use the method in a human population, scientists would need to know how many of the olfactory neurons to destroy and how often, Dillin said.

Because once the sense of smell comes back, the weight could also return.

Maybe once a year you block your sense of smell for a while and then you lose the weight from the year and do it all over again, Dillin said. We dont know yet. Theres a lot we still need to do.

Alison Graham is a San Francisco Chronicle staff writer. Email: agraham@sfchronicle.com Twitter: @alisonkgraham

Continued here:
Just smelling food can make you fat, UC Berkeley study says - SFGate

Read More...

Hair follicle growth by stromal vascular fraction-enhanced adipose transplantation in baldness – Dove Medical Press

July 11th, 2017 9:49 am

Video abstract presented by David Perez-Meza

Views: 58

David Perez-Meza,1 Craig Ziering,2 Marcos Sforza,3 Ganesh Krishnan,4 Edward Ball,5 Eric Daniels6

1Ziering Medical, Marbella, Spain; 2Ziering Medical, Los Angeles, CA, USA; 3The Hospital Group, Bromsgrove, Worcestershire, 4Ziering Medical, Birmingham, 5Ziering Medical, London, UK; 6Kerastem Technologies, San Diego, CA, USA

Abstract: Great interest remains in finding new and emerging therapies for the treatment of male and female pattern hair loss. The autologous fat grafting technique is >100 years old, with a recent and dramatic increase in clinical experience over the past 1015 years. Recently, in 2001, Zuk etal published the presence of adipose-derived stem cells, and abundant research has shown that adipose is a complex, biological active, and important tissue. Festa etal, in 2011, reported that adipocyte lineage cells support the stem cell niche and help drive the complex hair growth cycle. Adipose-derived regenerative cells (also known as stromal vascular fraction [SVF]) is a heterogeneous group of noncultured cells that can be reliably extracted from adipose by using automated systems, and these cells work largely by paracrine mechanisms to support adipocyte viability. While, today, autologous fat is transplanted primarily for esthetic and reconstructive volume, surgeons have previously reported positive skin and hair changes posttransplantation. This follicular regenerative approach is intriguing and raises the possibility that one can drive or restore the hair cycle in male and female pattern baldness by stimulating the niche with autologous fat enriched with SVF. In this first of a kind patient series, the authors report on the safety, tolerability, and quantitative, as well as photographic changes, in a group of patients with early genetic alopecia treated with subcutaneous scalp injection of enriched adipose tissue. The findings suggest that scalp stem cell-enriched fat grafting may represent a promising alternative approach to treating baldness in men and women.

Keywords: stem cell, alopecia, adipose, stromal vascular fraction, transplantation

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original here:
Hair follicle growth by stromal vascular fraction-enhanced adipose transplantation in baldness - Dove Medical Press

Read More...

100-year-old woman says the key to longevity is drinking wine – Globalnews.ca

July 11th, 2017 9:48 am

The secret to living to 100? This woman is convinced its wine.

Florence Bearse of Bangor, Maine, who recently celebrated her 100th birthday, told WLBZ the key to living a long life is a glass of wine.

I like my wine. Dont take it away from me, she told the broadcaster.

On her birthday, Bearse drank a glass of red, and was also treated to birthday cake, gifts and balloons. Working in the restaurant industry, WLBZ notes, Bearse said she learned how to dedicate her life to serve others.

READ MORE: 100-year-old Doug Snair may be the luckiest Canadian alive

This isnt the first time booze has been lauded for leading to a long life. Other centenarians have attributed their longevity to alcohol: in 2016, Antonio Docampo, who was 107, drank a mix of brandy and red wine daily, Mic reports.

And 105-year-old Eileen Ash, a yoga-loving grandmother in Norwich, England, said two glasses of red wine every day was the true key to living a long and healthy life, the BBC reports.

Vancouver-basedregistered dietitian Desiree Nielsen says the official rule on moderate drinking within a healthy lifestyle, is to consume no more than one standard drink a day for women and two a day for men.

The clincher here is what constitutes a standard drink. A 750-ml bottle should pour five to six drinks. Some wine goblets can easily drain a third of the bottle, she tells Global News.

READ MORE: 100-year-old South Carolina woman marks birthday by attempting to break world record

There have been countless studies on the health benefits of wine, especially red wine. One University of Alberta report found a glass of red wine was equivalent to an hour at the gym, Huffpost U.K. reports, while another study found red wine in moderation could also be beneficial to heart health.

The vast majority of research points to the polyphenols in red wine not white being the beneficial component, Nielsen says. White wine is made by removing the skin of the grapes before fermentation, which is where most of the phytochemical compounds are found. So if youre drinking as part of a healthy lifestyle, red is the better choice.

However, Nielsen says, if you dont drink much, you shouldnt start just because of this research (or because of anecdotes told by booze-loving 100-year-olds). You can get plenty of anti-inflammatory polyphenols from berries, green tea and naturally processed cocoa, she says.

While there is evidence that a moderate amount of wine may have health benefits, we also have to weigh that against the potential risks for the individual, she explains. If there is a strong family history of cancer, it is worth noting that any amount of alcohol consumption above zero increases risk a bit.

READ MORE: Is wine actually good for you? We asked 2 Harvard-educated doctors

If anti-inflammatory living and cardiovascular health are concerns, she says, red wine isnt a bad idea.

To keep your body as healthy as possible, I recommend going at least two or three days without any alcohol consumption, in line with national guidelines. Even better, keep drinks to the weekend most weeks, but just remember, you cant save up your weekly allotment and spend it all in two days.

arti.patel@globalnews.ca

2017Global News, a division of Corus Entertainment Inc.

See original here:
100-year-old woman says the key to longevity is drinking wine - Globalnews.ca

Read More...

Want To Try Microblading In Joburg? – Longevity LIVE

July 11th, 2017 9:48 am

A wise person once said, Great eyebrows dont happen by chance. They happen by appointment.

Although microblading has been a popular procedure in Asia and in Europe for over 25 years now, its relatively new in South Africa. Meaning, there arent too many places to get your eyebrows done yet. However, there are a few studios and practices introducing it to satisfy the otherwise meagerness Joburg market. This procedure can be performed in many different ways. And, anyone with a tattoo license may perform the cosmetic procedure. Henceforth, the procedure may often be performed by untrained professionals. Given the nature of this procedure, it also comes highly advised to do some research to verify the credentials of the practitioner you select. Here are a few trusted professionals in Joburg to hopefully help make your decision.

Brow Specialist Samantha Divaris and her team of highly skilled professionals run thisdexterous studio in glamorousbustle of Melrose Arch. Diviaris boastsa Masters in Health and Skincare Therapy from the renowned Beauty Therapy Institute in Cape Town amongst other impressive qualifications. The self- confessed perfectionist developed her love and passion for eyebrows 13 years ago. Amongst her team is brow and microblading specialist Monique. 7 years of experience in the beauty industry and being internationally accredited explainjust some of Moniques credentials.

Positioned in Weltevreden Park, Roodepoort, the boutique hasonly been open since 2016. However, the boutique isowned by the incredibly impressiveJess Hollingdrake. Afterqualifyingwith international Masters Training in Microblading, Colour Knowledge and PigmentRemoval, Jess established herself as one of the first microblading artists in South Africa. This small boutique salon is situated in a small boutique garden setting.

Read more from the original source:
Want To Try Microblading In Joburg? - Longevity LIVE

Read More...

Stem cell advance brings bioengineered arteries closer to reality – Medical Xpress

July 11th, 2017 9:48 am

July 10, 2017 Arterial endothelial cells derived from human pluripotent stem cells express activated NOTCH1 (in red, which is an arterial endothelial cell marker) and CD144 (in white, which is a pan endothelial cell marker). Credit: The Morgridge Institute for Research

Stem cell biologists have tried unsuccessfully for years to produce cells that will give rise to functional arteries and give physicians new options to combat cardiovascular disease, the world's leading cause of death.

But new techniques developed at the Morgridge Institute for Research and the University of Wisconsin-Madison have produced, for the first time, functional arterial cells at both the quality and scale to be relevant for disease modeling and clinical application.

Reporting in the July 10 issue of the journal Proceedings of the National Academy of Sciences (PNAS), scientists in the lab of stem cell pioneer James Thomson describe methods for generating and characterizing arterial endothelial cellsthe cells that initiate artery developmentthat exhibit many of the specific functions required by the body.

Further, these cells contributed both to new artery formation and improved survival rate of mice used in a model for myocardial infarction. Mice treated with this cell line had an 83 percent survival rate, compared to 33 percent for controls.

"The cardiovascular diseases that kill people mostly affect the arteries, and no one has been able to make those kinds of cells efficiently before," says Jue Zhang, a Morgridge assistant scientist and lead author. "The key finding here is a way to make arterial endothelial cells more functional and clinically useful."

Cardiovascular disease accounts for one in every three deaths each year in the United States, according to the American Heart Association, and claim more lives each year than all forms of cancer combined. The Thomson lab has made arterial engineering one of its top research priorities.

The challenge is that generic endothelial cells are relatively easy to create, but they lack true arterial properties and thus have little clinical value, Zhang says.

The research team applied two pioneering technologies to the project. First, they used single-cell RNA sequencing to identify the signaling pathways critical for arterial endothelial cell differentiation. They found about 40 genes of optimal relevance. Second, they used CRISPR-Cas9 gene editing technology that allowed them to create reporter cell lines to monitor arterial differentiation in real time.

"With this technology, you can test the function of these candidate genes and measure what percentage of cells are generating into our target arterial cells," says Zhang.

The research group developed a protocol around five key growth factors that make the strongest contributions to arterial cell development. They also identified some very common growth factors used in stem cell science, such as insulin, that surprisingly inhibit arterial endothelial cell differentiation.

"Our ultimate goal is to apply this improved cell derivation process to the formation of functional arteries that can be used in cardiovascular surgery," says Thomson, director of regenerative biology at Morgridge and UW-Madison professor of cell and regenerative biology. "This work provides valuable proof that we can eventually get a reliable source for functional arterial endothelial cells and make arteries that perform and behave like the real thing."

Thomson's team, along with many UW-Madison collaborators, is in the first year of a seven-year project supported by the National Institutes of Health (NIH) on the feasibility of developing artery banks suitable for use in human transplantation.

In many cases with vascular disease, patients lack suitable tissue from their own bodies for use in bypass surgeries. And growing arteries from an individual patient's stem cells would be cost prohibitive and take too long to be clinically useful.

The challenge will be not only to produce the arteries, but find ways to insure they are compatible and not rejected by patients.

"Now that we have a method to create these cells, we hope to continue the effort using a more universal donor cell line," says Zhang. The lab will focus on cells banked from a unique population of people who are genetically compatible donors for a majority of the population.

Explore further: Exposure to cardiovascular risk factors linked with arterial distensibility in adolescence

More information: Jue Zhang el al., "Functional characterization of human pluripotent stem cell-derived arterial endothelial cells," PNAS (2017). http://www.pnas.org/cgi/doi/10.1073/pnas.1702295114

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Excerpt from:
Stem cell advance brings bioengineered arteries closer to reality - Medical Xpress

Read More...

Rancho Cordova’s Cesca Therapeutics acquiring Sacramento-based SynGen – Sacramento Business Journal

July 11th, 2017 9:47 am

Sacramento Business Journal
Rancho Cordova's Cesca Therapeutics acquiring Sacramento-based SynGen
Sacramento Business Journal
Rancho Cordova-based regenerative medicine company Cesca Therapeutics Inc. is acquiring SynGen Inc., a Sacramento-based developer of cellular processing technology. Under the deal, SynGen's assets will be folded into Cesca (Nasdaq: KOOL) ...
Cesca Therapeutics subsidiary acquires assets of Sacramento's SynGen Inc.Sacramento Bee
Cesca Therapeutics Acquires the Cell Processing Systems of SynGen Under Asset Acquisition AgreementNasdaq
Big Move for Cesca Therapeutics Inc (NASDAQ:KOOL)StockNewsUnion

all 20 news articles »

See the rest here:
Rancho Cordova's Cesca Therapeutics acquiring Sacramento-based SynGen - Sacramento Business Journal

Read More...

Regenerating the Body With Stem Cells Hype or Hope? – Labiotech.eu (blog)

July 11th, 2017 9:47 am

When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their discovery, a therapeutic breakthrough is still outstanding.

The overall stem cell therapy field has failed today to show a very clear cut clinical benefit, told me Georges Rawadi, VP for Business Development at Celyad. The field now needs some significant success to attract attention.

Even though investors prefer placing their bets on the hot T cell therapies these days, some stem cell technologies such as iPSCs are starting to get traction as big industry players are exploring the territory. Last year, Bayer and Versant threw $225M into the pot to launch BlueRock Therapeutics, a regenerative medicine company that plans to develop iPSC-based therapies. A year before, Fujifilm spent $307M to acquire the iPSC company Cellular Dynamics.

Although a big success story is still lagging behind, recent advances in the field argue that stem cells indeed have the potential to translate into effective therapies for currently intractable diseases. Heres an overview of what biotechs stem cells are up to!

Stem cell treatment is not a new concept hematopoietic stem cells (HSCs) were described as early as the 1960s and bone marrow transplants have been used to treat blood cancer for decades.

The reason that we get excited about stem cell therapies comes from our experience with the hematopoietic stem cells. If you want to see what a mature stem cell therapy is like, you only need to look at bone marrow transplantation explained James Peyer, Managing Partner at Apollo Ventures, who has a Ph.D. in stem cell biology.

According to Peyer, the hematopoietic stem cell field is one of the most active areas in the stem cell world right now, mainly fueled by our advances in the gene editing space. Tools like CRISPR and TALEN allow for the genetic modification of a patients own bone marrow stem cells, which can then be expanded and returned to the patient for the correction of a genetic defect.

Last year, regulators gave green light to one of the first therapies of this kind. Strimvelis, developed by GSK, consists of an ex vivo stem cell gene therapy to treat patients with the very rare type of Severe Combined Immunodeficiency (SCID). Using the patients own cells avoids the risk of graft versus host disease (GvHD), which still affects around 30% of people receiving a bone marrow transplant.

Small wonder that the CRISPR companies, CRISPR Therapeutics, Editas, and Intellia are all active in this field, with preclinical programs in a number hematological diseases.

To date, the most prominent stem cells in the clinic are mesenchymal stem cells (MSCs), which are moving through more than 300 registered clinical trials for a wide array of diseases. These cells are able to form a variety of tissues including bone, cartilage, muscle or fat, and can be readily harvested from patients or donors for use in autologous or allogeneic therapies.

While MSCs have deluded the biotech scene with good safety profiles in clinical trials, their actual regenerative potential remains controversial, and there have been a great number of clinical failures, which many blame on a lack of demonstrated mechanisms of action.

As Peyer explained, The problem here is that, as opposed to other adult stem cells, the MSC has been unclearly defined. We know roughly what it does but we dont fully understand the molecular mechanisms driving these cells. On top of being unclearly defined, the regenerative powers of MSCs have been massively over-claimed in the past.

Another reason for the lack of clinical benefit has also been attributed to the use of undifferentiated MSCs, as Rawadi explained to me. The Belgian biotech Celyad, which has been pioneering cell therapy in the cardiovascular space, is using bone-marrow derived autologous MSCs and differentiates them into cardiomyocyte precursors to produce new heart muscle in patients with heart failure.

Although the company missed its primary endpoint in a phase III trial last year, Celyad has staked out a patient subpopulation that showed significant improvement. Its technology still has the confidence of the FDA, which just handed out a Fast Track designation and Celyad is now planning a refined Phase III trial.

One of Celyads major competitors, Australian Mesoblast, is forging ahead using allogeneic MSCs with Phase III programs in heart failure, chronic low back pain (CLBP) due to disc degeneration, as well as a range of inflammatory conditions including GvHD and rheumatoid arthritis.

Although the ability of MSCs to regenerate tissues remains questionable, the Mesoblasts approach hinges on a body of evidence showing that MSCs can suppress inflammation and mobilize endogenous repair mechanisms through indirect effects on immune cells.

Indeed, the first-ever approved stem cell therapy, Prochymal, also depends on this mechanism. Prochymal was developed by US-based Osiris Therapeutics and in 2012 received Canadian approval to treat acute GvHD. But after Sanofi opted to shelve its partnership with Osiris prior to FDA approval, the biotech sold out its off-the-shelf stem cell platform to Mesoblast in a $100M deal.

In Belgium, companies like TiGenix and Promethera are also banking on the immunomodulatory properties of MSCs. The companies are developing treatments for patients with Crohns disease and liver diseases, respectively.

The ultimate hope for stem cell therapies has been to regenerate damaged or diseased tissues as found in diabetes, heart failure or blindness. Holostem Terapie Avanzate, a spin-off from the University of Modena and Reggio Emilia was the first company to move towards this goal.

Building on 20 long years of research, the biotech has developed Holoclar, the first and only autologous stem cell therapy (apart from bone marrow transplants) to enter the European market. Holoclar is based on limbal stem cells, located in a part of the eye called the limbus, which can be used to restore eyesight in patients that have lost sight due to burn injuries.

Meanwhile, UK-based Reneuron is developing off-the-shelf therapies that aim to restore the cognitive function of patients following a stroke. Backed by no other than Neil Woodford, the company recently raised an impressive 100M to advance its lead therapy to the market.

The biotechs fetal-derived neural stem cell line CTX was able to significantly reduce the disability of post-stroke patients in a Phase II trial and ReNeuron is now planning to push its candidate into pivotal trials.

A major question in the space a decade ago was safety. Today, theres been a lot of trials done that show that safety is not an issue. I think safety is kind of off the table but efficacy is still a question mark. And thats what were trying to deliver now, Olav Helleb, CEO of ReNeuron, told me.

While neural stem cells and other tissue-specific stem cells are able to regenerate the cells of a particular tissue, Embryonic Stem Cells (ESCs) and their engineered counterparts, iPSCs, are capable of making every cell type in the body, a property known as pluripotency. Pluripotent stem cells can also expand indefinitely in culture and their identification unlocked massive expectations for these cells to transform the regenerative medicine field.

Yet, these cells come with significant challenges associated with the safety of the final preparation. Apart from ethical issues surrounding ESCs, today, a lot of companies have been cautious about using these cells for therapy, because undifferentiated pluripotent cells can drive tumor formation, explained Rawadi. Since ESCs can, in principle, form every cell type, they can lead to the formation of teratomas.

A major reason for the fairly slow progress in the field is based on the difficulties of directing a pluripotent cell to exactly the cell type that is needed for cell therapy. We can readily drive the cells from the undifferentiated state to the differentiated state. However, getting those cells to pause anywhere in the middle of this continuum to yield progenitor cells is incredibly challenging, Peyer explained. Another challenge, he says, is to engraft the cells in the right place to enable them to become fully integrated.

Besides initial hurdles, companies like US-based Asterias or ViaCyte are now running the first Phase I/II trials with ESC-derived cells to treat patients with spinal cord injuries and to restore the beta cells in type I diabetes. So far, the eye has been the the dominant organ for many of the first human clinical trials with pluripotent stem cells, where the cells are assessed in diseases such as age-related macular degeneration (AMD) to restore the loss of the retinal epithelium.

Deriving retinal epithelium from pluripotent cells is relatively easy and in fact, researchers in Japan are now running the very first clinical trial using donor-derived iPSCs to treat patients with AMD. For reasons of safety and standardization, the trial is based on an allogeneic approach. However, since this doesnt offer an exact genetic match, allogeneic therapies raise the prospect of immune rejection, an issue that has been plaguing the use of ESCs.

But the scientists in Japan have contended that iPSC banks could potentially solve this problem. The team in Japan is currently establishing an iPSC bank, consisting of HLA-characterized cell lines from 5-10 different donors, which should match 3050% of Japans population.

Such haplobanks have the benefits of allogeneic cell therapy, namely cost-effectiveness and standardization, but you still have matching immune systems, Peyer agrees.

For now, this remains a vision for the future, but the potential seems enormous. As Julian Howell, CMO of ReNeuron, told me, iPSCs have still got an awful long way to go. For the iPSC program running in Japan, they recently acknowledged that it took about $1.5M and 6 months to treat each patient. Its a great idea but its still got some way to go before it reaches the scale that could get into the clinic.

Images via nobeastsofierce,Natali_ Mis,vchal/ Shutterstock

Read more here:
Regenerating the Body With Stem Cells Hype or Hope? - Labiotech.eu (blog)

Read More...

A brief look at the medical issues in the Charlie Gard case – ABC News

July 11th, 2017 9:46 am

Charlie Gard is a terminally ill British child whose parents are fighting for the right to take him to the United States for an experimental treatment. His case has gained international attention, including from Pope Francis and U.S. President Donald Trump.

The 11-month-old is being treated at London's Great Ormond Street Hospital, which maintained the experimental treatment was "unjustified" and might cause Charlie more suffering without doing anything to help him. The hospital planned to take the boy off life support, but petitioned for a new court hearing based on evidence from researchers at the Vatican's children's hospital and another facility outside of Britain.

Below is some background on the medical and legal issues behind Charlie's case:

WHAT IS MITOCHONDRIAL DISEASE?

Mitochondrial disease is the umbrella term for a number of rare conditions caused by genetic mutations that result in the failure of mitochondria, specialized compartments within most cells that supply the energy needed to sustain life and support organ function. When mitochondria fail, cells can be injured or die, causing organ systems to shut down. The brain, heart, muscles and lungs are most affected because they need the most energy.

Charlie suffers from a form of the disease known as infantile onset encephalomyopathic mitochondrial DNA depletion syndrome (MDDS.) It is specifically known as the RRM2B mutation of MDDS. There is no known cure.

WHAT IS THE TREATMENT HIS PARENTS WANT FOR CHARLIE?

Doctors in the United States have been experimenting with a treatment known as nucleoside therapy, which has shown success in reducing the symptoms of some types of mitochondrial disease in laboratory mice. The treatment has been administered to a small number of children who have also shown improvement.

However, the treatment has never been used on either mice or humans with the type of mitochondrial disease from which Charlie suffers, according to court documents.

HAS THE NUCLEOSIDE THERAPY BEEN USED BEFORE?

A boy named Arturito Estopinan in Baltimore was the first child to be given deoxynucleotide monophosphate, an experimental treatment that significantly extended the life of mice with the same condition as Arturito, known as TK2-related mitochondrial depletion syndrome.

Art Estopinan, the boy's father, met with Charlie's parents in London to share his experience. He stressed that while the therapy was a treatment, not a cure, his 6-year-old son was "getting stronger every day." Arturito still needs around the clock care. Estopinan and his wife, Olga, have given their lives over to caring for him, hoping that a cure will come one day. The sacrifices keep coming because "we love our son," he said.

"A lot of very smart doctors are unaware of these experimental medications," Estopinan said. "As a father, I cannot sit back and know that my son was saved and not be vocal in support of Charlie Gard receiving these meds."

A CRUEL DISEASE

Sian Harding, Director of the British Heart Foundation Cardiovascular Regenerative Medicine Center at Imperial College, described the difficulty of treating the disease that Charlie has.

"Mitochondrial diseases are cruel because they strike babies and young children, who rapidly deteriorate," Harding said. "It is because there is no cure that the scientific and medical community have concentrated on pre-conception mitochondrial therapy, and it has been an enormous advance that this is now licensed by the government. It allows parents with these mutations to have healthy children, though sadly, cannot help babies already born."

WHY IS IT UP TO THE COURTS AND NOT CHARLIE'S PARENTS?

Parents in Britain do not have the absolute right to make decisions for their children. It is normal for courts to intervene when parents and doctors disagree on the treatment of a child. The rights of the child take primacy, with the courts weighing issues such as whether a child is suffering and how much benefit a proposed treatment might produce.

Professor Dominic Wilkinson, director of medical ethics at the Oxford Uehiro Center for Practical Ethics, said decisions about life-sustaining treatment for a child are "fraught."

"Sadly, reluctantly, doctors and judges are justified in concluding that continuing life support is not always helpful for a child and is in fact doing more harm than good," Wilkinson said. "Providing comfort, avoiding painful and unhelpful medical treatments, supporting the child and family for their remaining time: sometimes that is the best that we can do, and the only ethical course."

Go here to see the original:
A brief look at the medical issues in the Charlie Gard case - ABC News

Read More...

Genetically modified food is too advanced for its out-of-date regulations – The Hill (blog)

July 11th, 2017 9:46 am

Last week, the USDA published a series ofquestionsseeking input to establish a National Bioengineered Food Disclosure Standard, as mandated by amendments to the Agricultural Marketing Act of 1946 that went into effect in July 2016.

TheNational Bioengineered Food Disclosure Standard Actrequires the Secretary of the Department of Agriculture to establish disclosure standards for bioengineered food. The Act preempts state-based labeling laws for genetically modified organisms (GMOs), such as those adopted inVermontlast year.

The USDA is considering public input on the disclosure standards untilJuly 17, 2017. Two key issues are under consideration. The first is whether certain genetic modifications should be treated as though they are found in nature for example, a mutation that naturally confers disease resistance in a crop. The second concerns what types of breeding techniques should be classified as conventional breeding among "conventional breeding" techniques are hybridization and the use of chemicals or radiation to introduce random genetic mutations.

These seemingly mundane questions strike at the heart of GMO controversies and implicate the use of breakthrough CRISPR gene editing technologies. Gene editing allows novel and precise genetic modifications to be introduced into crops and animals intended for human consumption. The answers to the USDA's questions are significant because the Disclosure Standard Act exempts from mandatory disclosure genetic modifications obtained without recombinant DNA (rDNA) techniques that can otherwise be found in nature.

However, CRISPR gene editing need not rely on using any foreign DNA and can introduce genetic modifications that mirror those already found in nature. Unlike rDNA and conventional breeding methods, CRISPR technologies introduce genetic changes with far greater accuracy and precision.

In 2016, the USDAdeclined to regulatetwo CRISPR crops a mushroom and a waxy corn under regulations governing traditionalGMOs. But other regulatory agencies, including the FDA and EPA, have not yet made determinations on crops or animals modified with CRISPR technology, and uncertainty looms concerning the regulatory status of this new breed ofGMOs.

Opponents ofGMOs, who commonly argue thatGMOsare harmful to human health, decried the USDA's decision not to regulate CRISPR crops and argued thatpowerful corporations had found ways to circumvent the law through technical loopholes in outdated regulations.

Yet three decades of scientific research suggest that present-dayGMOcontroversies are not grounded in scientific fact. For instance, despite frequent rumors aboutGMO-induced cancers, a scientific consensus has now formed to support the health and environmental safety of genetically modified crops for animal and human consumption. That proposition is supported by investigations of theU.S. National Academies of Science, Engineering, and Medicineas well as scientific panels including the American Association for the Advancement of Science, the American Medical Association, the European Commission, and National Academies of Science in Australia, Brazil, China, France, Germany, India, the United Kingdom, and other countries.

In its rulemaking process, the USDA should rely upon science and facts. With regard to crops and animals with DNA altered through gene editing, rulemakers ought to distinguish among ways that CRISPR technology may be used to edit genes. For instance, CRISPR technology can be used as a DNA construct that is incorporated into the DNA of plant or animal cells, or as a preassembled RNA and protein complex.

How gene editing is carried out matters, because some methods appear to fall within the disclosure requirements while others do not. The law definesbioengineered foodas food that contains genetic material modified through in vitro rDNA techniques. Thus, under the Disclosure Standard Acts statutory constraints, CRISPR food created using DNA constructs that are incorporated into plant or animal cells would likely fall under the mandatory disclosures.

However, food derived from rDNA-free CRISPR gene editing using transient preassembled RNA and protein complexes should be excluded from the bioengineered food definition because such complexes are degraded shortly after gene editing takes place and do not insert themselves into the target organism DNA.

The nuances of ever-evolving biotechnological innovation highlight the complexity of our regulatory system and the need to modernize it. The National Bioengineered Food Disclosure Standard Act is just one of the latest pieces of that regulatory patchwork to emerge. Rules establishing bioengineered food disclosures should be coherent and science-based. Gene editing that uses no foreign DNA, is more precise than conventional breeding methods, and causes genetic modifications already found in nature should not be subject to onerous disclosure standards.

Paul Enrquez is a lawyer and scientist currently doing research in Structural & Molecular Biochemistry at North Carolina State University. His work focuses on the intersection of science and law and has been featured in both legal and scientific journals. He explores rising legal and regulatory issues concerning genome editing in crop production in depth and makes policy recommendations in his recently published article CRISPRGMOs.

The views expressed by contributors are their own and not the views of The Hill.

See the original post here:
Genetically modified food is too advanced for its out-of-date regulations - The Hill (blog)

Read More...

Combivent coupon – Is combivent and albuterol the same – Van Wert independent

July 11th, 2017 9:46 am

Submitted information

OHIO CITY The Ohio City Park Association and the Lambert Days Committee has finalized plans for the 2017 festival.

Lambert Days is always the third full weekend in July. This years dates are July 21-23. This is also the 50th anniversary of Ohio Citys celebration of the life of John W. Lambert and his invention of Americas first automobile.

This years edition of Lambert Days will feature a communitywide garage sale. For more information, contact Laura Morgan at 419.965.2515. There will also be food all weekend in the newly renovated Community Building on Ohio 118.

Friday, July 21

Festivities start off with a steak dinner (carryout is available), starting at 4 p.m. Friday. Ohio Citys American LegionHarvey Lewis Post 346 will have aflag-raising ceremony at 5 Friday evening, while kids games and inflatables will also open at 5. At 6 p.m., the Lambert Days Wiffleball Homerun Derby will take place. For more information, contactLorenzo Frye 419.771.7037.

There will also be entertainment at 6 p.m. featuring Cass Blue. At 7, there will be a adult Wiffleball tournament. For more information, contact Brian Bassett419.203.8203. A Texas Hold em Tournament will begin at 7 p.m. Friday, along with Monte Carlo Night, which begins at 8 p.m. For more information, contact Jeff Agler at 419.513.0580.

Entertainment for Friday night starts at 8 and will be the band Colt & Crew. There will also be a fireworks display at 10:15 p.m. Friday (Saturday night is the rain date).

Saturday, July 22

Saturday morning begins with a softball tournament at 8. For more information, contact Brian Bassettat 419.203.8203. There will also be a coed volleyball tournament that starts at 9 a.m. Saturday. For more information, contact Tim Matthews at 419.203.2976. The Lambert Days Kids Wiffleball Tournament starts at 10 a.m. Saturday. For more information, contact Lorenzo Frye at 419.771.7037.

Kids games and Inflatables continue at 11 Saturday morning. Cornhole tournament registration and 3-on-3 basketball tournament registration start at noon, while both tournaments begin at 1 p.m. For more information on cornhole, contact Josh Agler at 567.259.9941 and for 3-on-3 basketball, contact Scott Bigham at 419.953.9511.

The Hog Roast Dinner starts at 4 p.m. Saturday and carryout is available. There will also be music under the tent by Jeff Unterbrink at 4. Bingo will start at 5 p.m., and the night ends with entertainment by Megan White and Cadillac Ranch.

(more)

The rest is here:
Combivent coupon - Is combivent and albuterol the same - Van Wert independent

Read More...

Christchurch MS patient Andrea Cameron-Hill plans Russia trip for stem cell treatment – The Press

July 11th, 2017 9:46 am

JOEL INESON

Last updated14:01, July 9 2017

IAIN MCGREGOR/Stuff.co.nz

Andrea Cameron-Hill has lived with multiple sclerosis for about 10 years. She wants to receive treatment in Russia that could stop the disease.

Andrea Cameron-Hill thought having to lift her leg to get in the carwhile pregnant was part of carrying twins.

About 10 weeks after they were born she learned she had multiple sclerosis (MS).

"To start with, you wouldn't know I had MS at all. But now it's 10 years on and I'm having to walk with a crutch," she said.

IAIN MCGREGOR/STUFF

MS sufferer Cameron-Hill wants to receive treatment that could stop the disease in its tracks but, despite it being offered here to treat some cancer, must travel to Russia to get it.

"If I have to go down to the floor to load the fire with wood, the difficulty for me now is getting off the floor."

READ MORE: *Multiple sclerosis sufferer Royce Brewer cleared after experimental treatment in Russia *Multiple sclerosis patient to receive 'experimental' treatment in Russia *Friends rallying to help Upper Hutt woman reach Mexico for stem cell treatment *Marlborough woman's search for cure *Plea to help fund stem-cell treatment for Andrea Campbell *Hunt after cure for MS disease

Cameron-Hill has injured her shoulder fromfalls and reliedon her husband, Paul, and sons Lachlanand Oliverto help with household chores.

IAIN MCGREGOR/STUFF

Normal household chores like washing are a challenge because of the debilitating condition.

She wanted to do things like go onto the rugby field while her childrenplayed, but MS meant she had to watch from the car.

"We've got a basketball hoop [at home], which they quite like playing, but they normally play with Grandma because I can't."

"I feel like a spectator in their lives. I hate it. I hate it with a passion."

IAIN MCGREGOR/STUFF

Cameron-Hill's sons, Lachlan and Oliver, pictured, help her complete tasks many do effortlessly.

Cameron-Hill's condition drove herto look at a treatmentused in New Zealand for some forms of cancer, but not available for MS.

She plans to head to Russia for undergohematopoieticstem cell transplantation (HSCT).

HSCT would remove, purifyand concentrate her stem cells.Chemotherapy would wipeher immune system before the stem cells were returned. An extended period of recovery would follow.

IAIN MCGREGOR/STUFF

Cameron-Hill wants to take part in her children's lives, rather than watch from the sidelines.

Cameron-Hill mustraise about $80,000 to get the treatment.So far about $10,000 has been raised through fundraising events and aGivealittlepage.

Leading New Zealand neurologist Dr Deborah Mason said HSCT wasunlikely to be trialledin New Zealand because it wouldnot make drug companies money.

Treatment for MSin New Zealandreliesonimmunosuppressantdrugs.HSCTwaslikened more to a surgical procedure than drug treatment.

"It's incredibly expensive ... We're very keen to participate in [trials and research] and I'd certainly enroll patients, but it's just finding somebody who would fund that, and nobody will because there's no drug involved," Mason said.

Mason saidHSCT might help young patients in the early stages of MS.

She said the treatment was "unproven" and came with risks.

"It's really hard to imagine why I get all these calls about bone marrow transplants ... all bone marrow transplant allows us to [do is] give industrial doses of chemotherapy."

"People talk aboutrebootingthe immune system and all of that. There isn't a lot of proof of that."

Mason knew of about six or seven people who had travelled forHSCT, but did not have a lot of follow-updata.

Studies and clinical trials New Zealanders took part in primarily focussed on medication.

Her "big beef" was with the government not allowing the use of some drugs, "which we absolutely know will benefit the patients".

The Multiple Sclerosis Society of New Zealand recently changed its standpoint on HSCTafter a report indicated the treatment workedfor some with MS in Australia and the UK.

Vice president Neil Woodhams said the group asked the Ministry of Health to start a process to lead to eligible people havingHSCTin New Zealand.

Cameron-Hill's MS had not progressed since 2013and she had not been on medication for it since.

She recently met Christchurch manRoyce Brewer who lived with MS for about 20 years. After undergoing HSCT in Russia in early 2016, hereturned to work as a landscaper at the end of the year.

"I'd just really love to be able to do ... normal stuff that parents do with their kids," Cameron-Hill said.

The Health Research Council of New Zealandhad not funded any research regarding MS andHSCT, a spokeswoman said.

-Stuff

Follow this link:
Christchurch MS patient Andrea Cameron-Hill plans Russia trip for stem cell treatment - The Press

Read More...

Experts call for global action on unproven stem cell therapies – BioNews

July 11th, 2017 9:46 am

International experts are calling for global action on unproven and potentially dangerous stem cell therapies, and their misleading marketing to the public.

'Many patients feel that potential cures are being held back by red tape and lengthy approval processes. Although this can be frustrating, these procedures are there to protect patients from undergoing needless treatments that could put their lives at risk,' said Dr Sarah Chan from the University of Edinburgh. She is one of 15 authors who published the clarion call in the journal Science Translational Medicine.

Currently only few conditions can be successfully treated with stem cells, including blood cancers, some immune diseases, and severe burns.

Despite this, unlicensed clinics advertise stem cell-based treatments directly to patients promising a cure for various ailments when there is no evidence to show they will help, or that they will not cause harm.

The internet and social media have helped the burgeoning direct-to-consumer marketing of both licensed and unlicensed stem cell therapies, and 'offers sellers the ability to reach worldwide audiences, amplifying the difficulties of enforcing national laws in a global marketplace', note the authors.

They add that patients are vulnerable to these online marketing strategies due to the hyped media coverage of stem cell research; a lack of reliable information; and a combination of missing international guidelines and conflicting national regulations on procedures.

Foregoing alternative therapies, patients take risks on invalid stem cell-based procedures, which have led to deaths in Australia, Russia and Germany, warn the authors. While those who sell the treatments may be difficult to hold accountable due to legal grey areas on stem cell-based treatments in most countries.

In addition to the potential harm to patients, 'unfulfilled promises may bring regenerative medicine research and development into disrepute' the authors caution.

In their call for action, the experts from UK, the USA, Canada, Belgium, Italy and Japan urge for a cooperation of national and international efforts to control the global industry of stem cell-based medical procedures and their advertising.

The authors believe that 'predatory' clinics can be exposed on a national level, when scientific experts, investigative journalists and local authorities work together, such as in a recent trial of the Stamina Foundation in Italy, a highly publicized provider of unproven stem cell treatments (see BioNews 878).

They further suggest controls on advertising and international standards for the manufacture and testing of cell and tissue-based therapies, similar to global drug quality standards, which might be set by the World Health Organisation.

Such measures will only be effective when national governing bodies cooperate to ensure compliance, but the experts warn that 'the stakes are too high not to take a united stance'.

View original post here:
Experts call for global action on unproven stem cell therapies - BioNews

Read More...

Trump supporters know Trump lies. They just don’t care. – Vox

July 11th, 2017 9:46 am

During the campaign and into his presidency Donald Trump repeatedly exaggerated and distorted crime statistics. Decades of progress made in bringing down crime are now being reversed, he asserted in his dark speech at the Republican National Convention in July 2016. But the data here is unambiguous: FBI statistics show crime has been going down for decades.

CNNs Jake Tapper confronted Trumps then-campaign manager, Paul Manafort, right before the speech. How can the Republicans make the argument that somehow its more dangerous today, when the facts dont back that up? Tapper asked.

People dont feel safe in their neighborhoods, Manafort responded, and then dismissed the FBI as a credible source of data.

This type of exchange where a journalist fact-checks a powerful figure is an essential task of the news media. And for a long time, political scientists and psychologists have wondered: Do these fact checks matter in the minds of viewers, particularly those whose candidate is distorting the truth? Simple question. Not-so-simple answer.

In the past, the research has found that not only do facts fail to sway minds, but they can sometimes produce whats known as a backfire effect, leaving people even more stubborn and sure of their preexisting belief.

But theres new evidence on this question thats a bit more hopeful. It finds backfiring is rarer than originally thought and that fact-checks can make an impression on even the most ardent of Trump supporters.

But theres still a big problem: Trump supporters know their candidate lies, but that doesnt change how they feel about him. Which prompts a scary thought: Is this just a Trump phenomenon? Or can any charismatic politician get away with being called out on lies?

In 2010, political scientists Brendan Nyhan and Jason Reifler published one of the most talked about (and most pessimistic) findings in all of political psychology.

The study, conducted in the fall of 2005, split 130 participants into groups who read different versions of a news article about President George W. Bush defending his rationale for engaging in the Iraq War. One version merely summarized Bushs rationale There was a risk, a real risk, that Saddam Hussein would pass weapons or materials or information to terrorist networks. Another version of the article offered a correction that, no, there was not any evidence Saddam Hussein was stockpiling weapons of mass destruction.

The results were stunning: Staunch conservatives who saw the correction became more likely to believe Hussein had weapons of mass destruction. (In another experiment, the study found a backfire on a question about tax cuts. On other questions, like on stem cell research, there was no backfire.)

Backfire is a pretty radical claim if you think about it, Ethan Porter, a political scientist at George Washington University, says. Not only do attempts to correct information not sink in, but they can actually make conflicts even more intractable. It means earnest attempts to educate the public may actually making things worse. So in 2015, Porter and a colleague, Thomas Wood at the Ohio State University, set out to try to replicate the effect for a paper (which is currently undergoing peer review for publishing in the journal Political Behavior).

And among 8,100 participants and on the sort of political questions that tend to bring out hardline opinions Porter and Wood hardly found any evidence of backfire. (The one exception, interestingly, was the question of weapons of mass destruction in Iraq. But even on that, the backfire effect went away when they tweaked the wording of the question.)

Theres no evidence that backfire describes a common reflex of Americans when it comes to facts, Porter assures me. (Nyhan, for his part, never asserted that backfire was ubiquitous, just that it was a possible and particularly consequential result of fact-checking.)

Stories of failed replications in social psychology often grow ugly, with accusations of bullying and scientific misconduct flying in both directions. But in this story, researchers decided to team up to test the idea again.

The fact that Nyhan and Reiflers breakthrough study didnt replicate isnt a shocker. This happens all the time in science. One group of researchers publishes a breakthrough finding. Another lab tries to replicate it, and fails.

But instead of feuding, Nyhan, Reifler, Porter, and Wood came together to conduct a new study.

If you believe in social science, this is an ideal way to resolve a dispute, Porter says. If we can devise an experiment together, then the results are going to have something meaningful to say about our differing understandings of the world.

So the four researchers collaborated on two experiments with a wide range of people as subjects, including Trump and Hillary Clinton supporters.

The first experiment drew on Trumps exaggerations of crime statistics.

In the experiment, participants read one of five news articles. One was a control article about bird watching. Another just contained a summary of Trumps message without a correction. The third was an article that included a correction. The fourth included a correction, but then also a line of pushback from onetime Trump campaign manager Paul Manafort, who said the FBIs statistics were not to be trusted. The fifth included a line where Manafort really laid into the FBI, saying, "The FBI is certainly suspect these days after what they just did with Hillary Clinton.

The thinking here: If anyone should be able to incite a backfire effect among Trump supporters, its Trumps campaign director. Manafort gives Trump supporters cover. They can reject the correction and cite one of the most influential figures in the campaign. And if theres a time backfire ought to occur, its during a presidential campaign, when our political identities are fully activated.

But it didnt happen. On average, all the studys participants were more likely to accept the correction when they read it. Trump supporters were more hesitant to accept it than Clinton supporters. But thats not backfire; thats reluctance. Manaforts assertion that the FBI statistics were not to be trusted didnt make much of a difference either.

Everyones beliefs about changing crime over the last 10 years became more accurate in the face of a correction, Nyhan says.

The research group then conducted a second experiment during the presidential debates. This one was conducted in near-real time: On the night of the first presidential debate, the group ran an online study with 1,500-plus participants.

The study focused on one Trump claim in particular. Trump said thousands of jobs [are] leaving Michigan, Ohio ... theyre just gone.

This, again, isnt true. The Bureau of Labor Statistics actually finds both states created 70,000 new jobs in the previous year. Half of the participants saw the correction; the other half did not.

Again, the researchers found no evidence of backfire. Its worth underscoring: This was on the night of the first presidential debate. Its the Super Bowl of presidential politics. If corrections arent going to backfire during a debate, when will they?

In both experiments, the researchers couldnt find instance of backfire. Instead, they found that corrections did what they were intended to do: nudge people toward the truth. Trump supporters were more resistant to the nudge, but they were nudged all the same.

But heres the kicker: The corrections didnt change their feelings about Trump (when participants in the corrections conditions were compared with controls).

People were willing to say Trump was wrong, but it didnt have much of an effect on what they felt about him, Nyhan says.

So facts make an impression. They just dont matter for our decision-making, which is a conclusion thats abundant in psychology science.

(And if youre thinking, How could one short experimental manipulation really change how much participants like Trump? know that other research shows its possible. Notably, studies conducted during the election found that just reminding white voters they may be a racial minority one day increased support for Trump.)

The big question is: To what extent do those results generalize beyond Trump himself? says Nyhan. Many of his supporters may have to come to terms with his records of misstatements by the time this study was conducted. (The researchers did not test any fact-checks of Hillary Clinton talking points.)

Nyhan doesnt place blame on Trump supporters themselves; its just human nature to stand by our political partys candidates. But he says theres something wrong with our institutions, norms, and party leaders who enable the rise of candidates who constantly lie.

At least its nice to know that facts do make an impression, right? On the other hand, we tend to avoid confronting facts that run hostile to our political allegiances. Getting partisans to confront facts might be easy in the context of an online experiment. Its much harder to do in the real world.

These results have not yet been peer-reviewed or published in an academic journal so treat them as preliminary. But I did run them by several political science and psychology researchers for a sniff test.

These two experiments are well done, and the data analysis appears to straightforward and correct: we observe clear movement on subjects beliefs as a result of factual corrections, Alex Coppock, who researches political decision-making at Yale, writes in an email. This piece is nice because it adds to the (small but growing) consensus that backfire effects, if they exist at all, are rare.

Others commended the researchers for collaborating in the face of conflicting results. I think this is exactly how the scientific process should operate as we try to explain human behavior, Asheley Landrum, who researches politically motivated reasoning at Texas Tech, writes. Social scientists, arguably, should be even more aware of motivated reasoning, recognizing that it also occurs in scientists.

Nyhans research is about seeing if attitude change is possible. And this research often comes to frustrating ends. In one study, he and Reifler tested out four different interventions to try to nudge vaccine skeptics away from their beliefs. None made a difference. Though it is elusive, at the least, he found a little attitude change within himself.

Jason [Reifler] and I have definitely updated our beliefs about the prevalence of the backfire effect, Nyhan says. He wont say its been debunked. But hes moving in that direction.

Go here to read the rest:
Trump supporters know Trump lies. They just don't care. - Vox

Read More...

The BEER that’s good for you – THIS alcoholic drink boosts gut health and immune system – Express.co.uk

July 10th, 2017 1:45 pm

Drinking beer could soon come with added health benefits, thanks to a team of researchers in Singapore.

A new speciality beer now includes the probiotic strain Lactobacillus paracasei L26, which was first taken from human intestines.

The bacteria has the ability to neutralise toxins and viruses and even boost the immune system, the scientists claim.

Studies have shown that eating food and drink with live counts of probiotics are more effective in delivering health effects than eating those with inactive probiotics.

GETTY

Recommendations by the International Scientific Association for Probiotics and Prebiotics is to have a minimum of 1 billion probiotics per serving in order to attain the maximum health benefits.

The idea of a probiotic beer was the brainchild of student Chan Mei Zhi Alcine, who consumes dairy-based probiotic drinks daily.

The health benefits of probiotics are well known, she said.

While good bacteria are often present in food that have been fermented, there are currently no beers in the market that contain probiotics.

Developing sufficient counts of live probiotics in beer is a challenging feat as beers contain hop acids that prevent the growth and survival of probiotics.

1 of 11

GETTY

Developing sufficient counts of live probiotics in beer is a challenging feat

Miss Chan said the recipe, which included the optimal count of live probiotics - took nine months to develop.

For this beer, we used a lactic acid bacterium as a probiotic micro-organism, she said.

It will utilise sugars present in the wort to produce sour-tasting lactic acid, resulting in a beer with sharp and tart flavours.

The final product, which takes around a month to brew, has an alcohol content of about 3.5 per cent, said Miss Chan.

GETTY

The NUS research team has filed a patent to protect the recipe for brewing the probiotic sour beer.

Associate Professor Liu Shao Quan from the NUS Food Science and Technology Programme said: The general health benefits associated with consuming food and beverages with probiotic strains have driven demand dramatically.

In recent years, consumption of craft or specialty beers has gained popularity too.

Alcines invention is placed in a unique position that caters to these two trends.

I am confident that the probiotic gut-friendly beer will be well-received by beer drinkers, as they can now enjoy their beers and be healthy.

Here is the original post:
The BEER that's good for you - THIS alcoholic drink boosts gut health and immune system - Express.co.uk

Read More...

Page 988«..1020..987988989990..1,0001,010..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick